{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:49:48Z","timestamp":1782452988809,"version":"3.54.5"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>This article innovatively reviews and unveils the synergistic mechanisms, clinical research directions, and future challenges of the combination of preoperative radiotherapy (RT) and immunotherapy (especially the most popular belonging to immune checkpoint inhibitors, ICIs) in the treatment of locally advanced gastric cancer and gastroesophageal junction adenocarcinoma (GC\/GEA). The integration of RT and ICIs represents a promising therapeutic strategy for locally advanced, even unresectable, GC\/GEA. RT potentiates antitumor immunity by inducing immunogenic cell death (ICD) and targeting iron death, activating the cyclic Guanosine Monophosphate (GMP) and Adenosine Monophosphate (AMP) synthase-stimulator of interferon genes (STING protein) (cGAS-STING) signaling pathway, enhancing the expression level of the major histocompatibility complex (MHC) molecule and immune checkpoint proteins on tumor cells, and promoting immune cell infiltration into the tumor micro-environment. Trials with small sample sizes, such as Neo-PLANET and SHARED, have demonstrated that neoadjuvant chemoradiotherapy (NCRT) combined with ICIs yields encouraging pathological complete response (pCR, ranging from 22.6% to 38.2%) and high R0 resection rates with manageable toxicity profiles. Nevertheless, conflicting results from phase I-II trials like ECOG-ACRIN EA2174 underscore the necessity for patient stratification based on robust biomarkers. Current evidence regarding tumor cell programmed cell death protein ligand 1 (PD-L1) expression (namely, PD-L1 combined positive score or tumor proportion score), tumor mutational burden (TMB), and intratumoral immune micro-environment features for identifying responders still remains inconclusive. Future efforts should prioritize the validation of predictive biomarkers (containing the cutting-edge ctDNA), RT dose, and target area definition (especially for primary positive tumors and high-risk lymphatic drainage); optimization of RT-ICIs sequencing; and the conduct of large-scale randomized controlled trials to establish survival benefits and standardize combination protocols according to the stratified population.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1875451","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:56Z","timestamp":1782452696000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergizing radiotherapy and immunotherapy for locally advanced gastric cancer: evolving paradigms and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuhui","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Nanshan People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Pu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Nanshan People\u2019s Hospital","place":["Shenzhen, China"]},{"name":"Department of Radiation Oncology and Shenzhen Proton Therapy Center, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]},{"name":"Medical Department of Shenzhen University\/General Hospital of Shenzhen University\/Academy of Clinical Medicine of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Shenzhen Proton Therapy Center, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqin","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Shenzhen Proton Therapy Center, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Nanshan People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Nanshan People\u2019s Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, South China Hospital, Medical School, Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Shenzhen Proton Therapy Center, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shenzhen Nanshan People\u2019s Hospital","place":["Shenzhen, China"]},{"name":"Medical Department of Shenzhen University\/General Hospital of Shenzhen University\/Academy of Clinical Medicine of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Shenzhen Proton Therapy Center, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Shenzhen, China"]},{"name":"State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.744839","article-title":"Recent advances in the diagnosis, staging, treatment, and prognosis of advanced gastric cancer: A literature review","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01156-9","article-title":"Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons","author":"Zhu","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1038\/s41467-025-62056-7","article-title":"Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study","volume":"16","author":"Zaanan","year":"2025","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The randomized controlled CROSS trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative chemoradiotherapy for resectable gastric cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.03.044","article-title":"Long-term prognostic analysis of chemoradiation therapy versus chemotherapy after D2 resection for high-risk gastric cancer: results from a prospective randomized control study","volume":"123","author":"Qiao","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00676-4","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1733349","article-title":"An analysis of tolerance and early survival outcomes with perioperative modified FLOT in gastric cancers","volume":"11","author":"Bhargava","year":"2022","journal-title":"South Asian J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4840","article-title":"Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response","volume":"24","author":"Ajani","year":"2006","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554114","article-title":"The tumor microenvironment across four dimensions: assessing space and time in cancer biology","volume":"16","author":"Larson","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529403","article-title":"Recent advances in novel tumor immunotherapy strategies based on regulating the tumor microenvironment and immune checkpoints","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00243-1","article-title":"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial","volume":"8","author":"Reynolds","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.08.024","article-title":"A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection","volume":"104","author":"Zhu","year":"2012","journal-title":"Radiother Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S0140-6736(26)00974-8","DOI":"10.1016\/S0140-6736(26)00974-8","article-title":"ASTRUM-006 Study Group. Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study","volume":"1","author":"Shen","year":"2026","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02842","article-title":"Perioperative toripalimab plus chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of NEOSUMMIT-01 trial","author":"Nie","year":"2026","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103568","article-title":"Perioperative camrelizumab and apatinib combined with chemotherapy for locally advanced gastric cancer in China: three-year survival outcomes of phase 2 randomized controlled trial","volume":"89","author":"Lin","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1035884","article-title":"Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance","volume":"12","author":"Voronova","year":"2022","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1038\/s41467-020-19970-9","article-title":"Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death","volume":"11","author":"Hayashi","year":"2020","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ccell.2023.05.005","article-title":"Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity","volume":"41","author":"Fang","year":"2023","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0028-4","article-title":"Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity","volume":"1","author":"Carozza","year":"2020","journal-title":"Nat Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","article-title":"Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy","volume":"122","author":"Garland","year":"2022","journal-title":"Chem Rev"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS-STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-01224-3","article-title":"GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer","volume":"8","author":"Long","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101366","article-title":"Radiotherapy: brightness and darkness in the era of immunotherapy","volume":"19","author":"Zhai","year":"2022","journal-title":"Transl Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2023.151338","article-title":"Cancer cell-specific cGAS\/STING signaling pathway in the era of advancing cancer cell biology","volume":"102","author":"Kumar","year":"2023","journal-title":"Eur J Cell Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-031920-093932","article-title":"Opposing roles of type I interferons in cancer immunity","volume":"16","author":"Boukhaled","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0338","article-title":"Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11","volume":"9","author":"Lang","year":"2019","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102251","article-title":"Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials","volume":"16","author":"Pu","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.05.009","article-title":"Durvalumab after concurrent chemoradiotherapy in elderly patients with unresectable stage III non-small-cell lung cancer (PACIFIC)","volume":"22","author":"Socinski","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: Durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.12.006","article-title":"Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: The ADRIATIC study","volume":"21","author":"Senan","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.226","article-title":"Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of Malignant esophago-gastric diseases (PROCEED): assessment of pathologic response in a prospective, phase II single-arm trial","author":"Karukonda","year":"","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/s41467-023-40480-x","article-title":"Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0413","article-title":"Pembrolizumab in combination with neoadjuvant chemoradiotherapy for patients with resectable adenocarcinoma of the gastroesophageal junction","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4000","article-title":"A phase II\/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)","volume":"42","author":"Eads","year":"2024","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.075","article-title":"Neoadjuvant toripalimab plus concurrent chemoradiotherapy in the locally advanced adenocarcinoma of esophagogastric junction: a phase II trial","author":"Du","year":"","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4034","article-title":"Phase I\/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II\/III resectable esophageal and gastroesophageal junction (E\/GEJ) cancer","volume":"40","author":"Uboha","year":"2022","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","article-title":"Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial","volume":"25","author":"Fuchs","year":"2022","journal-title":"Gastric Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.358","article-title":"INFINITY: a multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC\/GEJAC)","volume":"41","author":"Filippo","year":"2023","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.006","article-title":"Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy","volume":"43","author":"Wang","year":"2025","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.04.07","article-title":"Potential value of detection of minimal residual disease in colorectal cancer following radical resection","volume":"36","author":"Pu","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.34133\/cancomm.0006","article-title":"Preoperative chemoradiotherapy versus chemotherapy for locally advanced gastric cancer or gastroesophageal junction adenocarcinoma: a phase III randomized controlled trial from China","volume":"46","author":"Liu","year":"2026","journal-title":"Cancer Commun (Lond)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686142","article-title":"Cancer cells can exhibit a sparing FLASH effect at low doses under normoxic in vitro-conditions","volume":"11","author":"Adrian","year":"2021","journal-title":"Front Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1357101","article-title":"Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001119","article-title":"Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00052-2","article-title":"Gastric cancer","volume":"405","author":"Sundar","year":"2025","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100845","article-title":"Gastric cancer-epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: an updated review","volume":"41","author":"Mamun","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1638316","article-title":"Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric\/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial","volume":"16","author":"Meng","year":"2025","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00447","article-title":"Neoadjuvant CTLA-4\/PD-(L)1 blockade versus surgery +\/- chemotherapy in deficient mismatch repair\/microsatellite instability-high resectable gastroesophageal adenocarcinoma: individual patient data pooled analysis","volume":"43","author":"Raimondi","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:44:57Z","timestamp":1782452697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":80,"alternative-id":["10.3389\/fimmu.2026.1875451"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1875451","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1875451"}}